Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

2026-02-22 13:05:39 ET

Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Redmile Group increased its position in Krystal Biotech by 16,317 shares. The estimated transaction value was $3.43 million, calculated using the average closing price for the fourth quarter of 2025. The total value of Redmile’s stake in Krystal Biotech at quarter-end rose by $50.33 million, driven by both share purchases and price appreciation.

Krystal Biotech is a biotechnology company focused on innovative gene therapy solutions for underserved rare disease markets. The company’s strategy centers on advancing a differentiated pipeline of redosable gene therapies, targeting both dermatological and respiratory indications. With a strong clinical-stage portfolio and a focus on commercialization, Krystal Biotech aims to address significant unmet medical needs and establish a leadership position in gene therapy for rare diseases.

Continue reading